


EUKARYS

The Synthetic Gene Therapy Company



EuroQuity, E-pitch session
June 9, 2020

PROJECT IDEA

To develop a pipeline of synthetic gene therapies – a novel therapeutic approach for gene compensation, also adaptable to vaccination - able to fill unmet needs of existing gene therapy approaches

PROBLEM

- Gene therapy technologies existing to date, primarily based on recombinant viruses, have many drawbacks:

- Safety: insertional mutagenesis,
- Immunogenicity: readministration,
- IFN response: tolerance,
- Gradual collapse of efficiency,
- Packaging capacity: gene length,
- Tissue-specific targeting,
- Very expensive production process,

Limited to monogenic diseases.

* Other technical developments are on going for synthetic gene vaccination


SOLUTION

Synthetic gene therapy is made possible by two technologies invented and developed by Eukarys*

- ① Synthetic DNA produced with Möbius® system



- ② C3P3® artificial expression system



C3P3-G1: WO 2011/128444 → 2031 - C3P3-G2: EP2018/070479 → 2037 - C3P3-G3: on-going

COMPETITION

- Viral gene therapy:
 - Main competitor with most products registered in the last 5 years,
 - Competitors: Novartis, Pfizer, Spark, UniQure, BluebirdBio, Immune Design, Audentes...
- The other approaches have not demonstrated their effectiveness:
 - Synthetic mRNA (except for vaccination),
 - Viral gene therapy with plasmid DNA.
- Main competitor for synthetic gene vaccination: synthetic mRNA (Moderna, Curevac, BioNTech)


EXPECTED ADVANTAGES

- ❑ Safe: without risk of insertional mutagenesis,
- ❑ Well-tolerated: without CpG dinucleotides
- ❑ Immuno-masked: for the enzyme C3P3,
- ❑ Transient and readministrable,
- ❑ Expression and/or inhibition of one or more genes,
- ❑ No known limits in gene length,
- ❑ GMP-compliant with reduced production costs,
- ❑ Conjugated with small molecules or others technology for synthetic gene vaccination

MARKET OPPORTUNITY & TRACTION

- Gene therapy is rapidly growing market:
 - Gene therapy market US\$9.7 billion, with CAGR of 36% → US\$45 billion in 2025,
 - FDA: 10-20 CGT predicted to be approved per year by 2025, >200 CGT IND expected to be submitted by 2020,
 - Estimates to be taken with caution: e.g. commercial failure of Glybera (Unique).
- Nucleic acid vaccination accounted for US\$ 8.99 Mn in 2019, and was expected to grow at a CAGR of 61.5% ... before the Covid-19 pandemics

REVENUE MODEL



Bioproduction

TEAM



Executive

Board of Directors

Special Advisory

Scientific Advisory Board

Philippe Jais

Executive President & CSO,
 Founder of Eukarys
 Inventor of all technologies
 MD (Hepato-gastroenterology), PhD
 (Molecular Genetics)
 Pharma and Biotech

Patrice Vernet

Experienced entrepreneur,
 Former elected representative of
 Essonne
 Historical investor

Pr. Pierre Chambon

Emeritus Professor of Biochemistry
 IGMC and ICS, Strasbourg
 Professor Collège de France
 Albert Lasker Award Member of the
 French, Swedish and US National
 Academy of Sciences

Dr. Daniel Metzger

Research Director at CNRS
 IGMC and ICS, Strasbourg
 Grand Prix Jules Martin
 Prix René Turpin
 Member of European Academy of
 Cancer Sciences and EMBO

Thierry Doueb

Administrator
 Attorney at law
 University of Paris II Panthéon-Assas
 Institute of Political Studies (Sciences-
 Po – EcoFi)
 Historical investor

Pierre Grange

Administrator
 Ecole des Ponts et Chaussées,
 Former President of SORIF (Vinci
 Immobilier Trust
 President of IDEVI
 Historical investor

Pr. Philippe Kourilsky

Professor of Immunology
 Former CEO of Paris Pasteur Institute
 Professor Collège de France
 Former Chairman of the Singapore
 Immunology Network

Pr. Christian Bréchet

Professor of Hepatology
 Paris Descartes University Former
 Former CEO of INSERM
 Former CEO of Paris Pasteur Institute
 President Global Virus Network



Guillaume Prunier

Special advisor
 Polytechnique/Mines
 Areva, head of innovation French
 Ministry of Economy, former CEO
 Flaminem
 Deputy Executive Director, INRIA



Pr. Dominique Franco

Administrator
 Emeritus Professor of Surgery
 University Paris XI
 Expert in liver surgery
 Pioneer of liver transplantation
 President of the French Academy of
 Surgery



Fabrice Aurousseau

Administrator
 Institute of Political Studies,
 Sorbonne Law School, Edmond de
 Rothschild, BNP Paribas, SFAF
 Eponyme Partners.
 President of PPRS



Pr. Jean-Charles Duclos-Vallée

Professor of Hepatology
 University Paris XI
 Expert in severe acute and chronic
 liver diseases
 Head of the DHU Hepatinov, Paris



Dr. Steve Pascolo

PhD, ENS of Paris
 Former CSO of Curevac
 Pioneer of mRNA uses for vaccination
 and immunomodulation
 Head of Immunology, University
 Hospital of Zürich

FINANCIALS

- Economic model dependent on investment by private investors, i.e. business angels, family offices and VCs.
- Objectives:
 - To reach to clinical POC with our most advanced synthetic gene therapy,
 - Followed by co-development agreement with Pharma,
 - Expected in 2024.
- Estimated financial needs: €18 million to reach final objective in several tranches.

INVESTMENT

- ▣ Amount sought: €2.5 million,
- ▣ Target period: 3Q or 4Q 2020,
- ▣ Uses of the funds:
 - ▣ Recruitment of key people: CEO, CFO part time, R&D staff,
 - ▣ R&D: CMC of synthetic DNA of EUK-LR up to submission to regulatory agencies,
 - ▣ Intellectual Property

Eukarÿs: mRNA is our DNA! ®





Accelerated by
Health

EIT Health is supported by the EIT,
a body of the European Union.

THE MOST INNOVATIVE COMPANIES IN
10 GENE THERAPY



Eukarÿs
Genopole Campus 3
4 rue Pierre Fontaine
91000 Evry, France
contact@eukarys.com



PRIX GALIEN
MEDSTARTUP